Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010
Do we really need another book on the treatment of multiple sclerosis (MS)? Hardly another field in neurology is currently moving as fast as the entire field of neuroimmunology, and the treatment of MS in particular. One could argue that especially in fast-moving fields the publication of books is useless, since already the delay between writing, publishing, and distributing will attenuate the topicality of its content. On the other hand, neuroimmunology is not only a fast-moving field but its current development is also diverse and encompasses many new directions, therapeutic targets, and agents. For the clinical neurologist, even with a special interest in neuroimmunological disorders, it becomes increasingly difficult to keep track, with more than 300 ongoing clinical trials in MS and its related disorders. Hence, the final answer to whether we really need another book on the treatment of MS is a clear yes, as long as the book has comprehensive information on current therapeutic concepts, ongoing developments and changes in these current concepts, and new approaches neurologists will be exposed to in the very near future.
Treatment of Multiple Sclerosis. Arch Neurol. 2010;67(8):1031. doi:10.1001/archneurol.2010.165
Customize your JAMA Network experience by selecting one or more topics from the list below.